Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Revolution Medicines (RVMD) EBIT Margin (2019 - 2025)

Revolution Medicines (RVMD) has 6 years of EBIT Margin data on record, last reported at 2758.74% in Q3 2025.

  • For Q3 2025, EBIT Margin changed N/A year-over-year to 2758.74%; the TTM value through Dec 2025 reached 2078.87%, changed N/A, while the annual FY2023 figure was 4207.12%, 347711.0% down from the prior year.
  • EBIT Margin reached 2758.74% in Q3 2025 per RVMD's latest filing, up from 24256.47% in the prior quarter.
  • Across five years, EBIT Margin topped out at 2758.74% in Q3 2025 and bottomed at 24256.47% in Q4 2023.
  • Average EBIT Margin over 4 years is 2984.36%, with a median of 722.9% recorded in 2022.
  • Peak YoY movement for EBIT Margin: soared 254813bps in 2022, then crashed -2385394bps in 2023.
  • A 4-year view of EBIT Margin shows it stood at 559.33% in 2021, then increased by 28bps to 402.52% in 2022, then tumbled by -5926bps to 24256.47% in 2023, then surged by 111bps to 2758.74% in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT Margin were 2758.74% in Q3 2025, 24256.47% in Q4 2023, and 2845.11% in Q2 2023.